Core Insights - Inspira Technologies announced a strategic commercial showcase of its FDA-cleared INSPIRA™ ART100 system at the AmSECT 64th International Conference, scheduled for March 25–29, 2026, in Austin, Texas [1][4] Group 1: Commercial Strategy - The showcase aims to engage directly with decision-makers in hospitals, enhancing the company's U.S. commercial strategy and expanding clinical partnerships and distribution [3][7] - The ART100 system has received FDA 510(k) clearance, validating its readiness for clinical integration in cardiopulmonary bypass procedures [7] Group 2: Product Overview - The INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., serving as a foundation for the development of the next-generation INSPIRA ART500 system [5] - The company is also advancing the HYLA™ blood sensor platform, which offers continuous, non-invasive monitoring [5] Group 3: Industry Context - The AmSECT International Conference is a key global event for perfusion technology, featuring cutting-edge medical technologies and expert-led sessions [4]

Core Insights - Inspira Technologies has successfully completed the first human treatment using its FDA-cleared INSPIRA ART100 system in a critical life-support procedure, marking a significant milestone for the company [1][2][3] - The procedure was performed at Westchester Medical Center, where the INSPIRA ART100 provided effective heart and lung support, demonstrating its clinical readiness and reliability [2][3] - The company aims to expand the clinical use of the INSPIRA ART100 across leading hospitals in collaboration with its U.S. distributor, Glo-Med Networks Inc. [3][4] Company Overview - Inspira Technologies specializes in developing innovative respiratory support and diagnostic technologies, with its flagship product being the INSPIRA ART500 system, which aims to revolutionize critical care [4] - The INSPIRA ART100 system has received regulatory approvals for cardiopulmonary bypass procedures in both the U.S. and Israel, showcasing its potential in critical care settings [4] - The company's HYLA blood sensor technology is designed for continuous, real-time blood monitoring without the need for blood draws, indicating a focus on advancing medical technology [4] Collaboration and Market Strategy - Glo-Med Networks Inc. is responsible for the installation, training, and professional services related to the clinical use of the INSPIRA ART100, highlighting the importance of partnerships in the company's strategy [3][6] - Glo-Med has extensive access to next-generation medical products globally, which could facilitate the broader adoption of Inspira's technologies in various markets [6]